Search Results - "Budczies, J."

The journey of tumor-infiltrating lymphocytes as a biomarker in breast cancer: clinical utility in an era of checkpoint inhibition by Loi, S., Michiels, S., Adams, S., Loibl, S., Budczies, J., Denkert, C., Salgado, R.

“…In 2014, we described a method to quantify percentage of tumor-infiltrating lymphocytes (TILs) on hematoxylin and eosin-stained slides of breast cancer samples…”
Get full text

Optimizing panel-based tumor mutational burden (TMB) measurement by Budczies, J., Allgäuer, M., Litchfield, K., Rempel, E., Christopoulos, P., Kazdal, D., Endris, V., Thomas, M., Fröhling, S., Peters, S., Swanton, C., Schirmacher, P., Stenzinger, A.

“…Panel sequencing based estimates of tumor mutational burden (psTMB) are increasingly replacing whole exome sequencing (WES) tumor mutational burden as…”
Get full text

Identification of a highly lethal V3+TP53+ subset in ALK+ lung adenocarcinoma by Christopoulos, P., Kirchner, M., Bozorgmehr, F., Endris, V., Elsayed, M., Budczies, J., Ristau, J., Penzel, R., Herth, F.J., Heussel, C.P., Eichhorn, M., Muley, T., Meister, M., Fischer, J.R., Rieken, S., Lasitschka, F., Bischoff, H., Sotillo, R., Schirmacher, P., Thomas, M., Stenzinger, A.

“…Tyrosine kinase inhibitors (TKI) have improved prognosis in metastatic anaplastic lymphoma kinase (ALK)‐driven lung adenocarcinoma, but patient outcomes vary…”
Get full text

Ki67 levels as predictive and prognostic parameters in pretherapeutic breast cancer core biopsies: a translational investigation in the neoadjuvant GeparTrio trial by Denkert, C., Loibl, S., Müller, B.M., Eidtmann, H., Schmitt, W.D., Eiermann, W., Gerber, B., Tesch, H., Hilfrich, J., Huober, J., Fehm, T., Barinoff, J., Jackisch, C., Prinzler, J., Rüdiger, T., Erbstößer, E., Blohmer, J.U., Budczies, J., Mehta, K.M., von Minckwitz, G.

“…The proliferation marker Ki67 has been suggested as a promising cancer biomarker. As Ki67 needs an exact quantification, this marker is a prototype of a new…”
Get full text

Tumour cell proliferation (Ki-67) in non-small cell lung cancer: a critical reappraisal of its prognostic role by Warth, A, Cortis, J, Soltermann, A, Meister, M, Budczies, J, Stenzinger, A, Goeppert, B, Thomas, M, Herth, F J F, Schirmacher, P, Schnabel, P A, Hoffmann, H, Dienemann, H, Muley, T, Weichert, W

“…Background: Uncontrolled proliferation is a hallmark of malignant tumour growth. Its prognostic role in non-small cell lung cancer (NSCLC) has been…”
Get full text

The German Network for Personalized Medicine to enhance patient care and translational research by Illert, A. L., Stenzinger, A., Bitzer, M., Horak, P., Gaidzik, V. I., Möller, Y., Beha, J., Öner, Ö., Schmitt, F., Laßmann, S., Ossowski, S., Schaaf, C. P., Hallek, M., Brümmendorf, T. H., Albers, P., Fehm, T., Brossart, P., Glimm, H., Schadendorf, D., Bleckmann, A., Brandts, C. H., Esposito, I., Mack, E., Peters, C., Bokemeyer, C., Fröhling, S., Kindler, T., Algül, H., Heinemann, V., Döhner, H., Bargou, R., Ellenrieder, V., Hillemanns, P., Lordick, F., Hochhaus, A., Beckmann, M. W., Pukrop, T., Trepel, M., Sundmacher, L., Wesselmann, S., Nettekoven, G., Kohlhuber, F., Heinze, O., Budczies, J., Werner, M., Nikolaou, K., Beer, A. J., Tabatabai, G., Weichert, W., Keilholz, U., Boerries, M., Kohlbacher, O., Duyster, J., Thimme, R., Seufferlein, T., Schirmacher, P., Malek, N. P.

Get full text

Cancer beyond organ and tissue specificity: Next‐generation‐sequencing gene mutation data reveal complex genetic similarities across major cancers by Heim, D., Budczies, J., Stenzinger, A., Treue, D., Hufnagl, P., Denkert, C., Dietel, M., Klauschen, F.

“…Cancer medicine relies on the paradigm that cancer is an organ‐ and tissue‐specific disease, which is the basis for classifying tumors. With the extensive…”
Get full text

Reconstructing tumor history in breast cancer: signatures of mutational processes and response to neoadjuvant chemotherapy by Denkert, C., Untch, M., Benz, S., Schneeweiss, A., Weber, K.E., Schmatloch, S., Jackisch, C., Sinn, H.P., Golovato, J., Karn, T., Marmé, F., Link, T., Budczies, J., Nekljudova, V., Schmitt, W.D., Stickeler, E., Müller, V., Jank, P., Parulkar, R., Heinmöller, E., Sanborn, J.Z., Schem, C., Sinn, B.V., Soon-Shiong, P., van Mackelenbergh, M., Fasching, P.A., Rabizadeh, S., Loibl, S.

“…Different endogenous and exogenous mutational processes act over the evolutionary history of a malignant tumor, driven by abnormal DNA editing, mutagens or…”
Get full text

Pan-cancer analysis of genomic scar patterns caused by homologous repair deficiency (HRD) by Rempel, E., Kluck, K., Beck, S., Ourailidis, I., Kazdal, D., Neumann, O., Volckmar, A. L., Kirchner, M., Goldschmid, H., Pfarr, N., Weichert, W., Hübschmann, D., Fröhling, S., Sutter, C., Schaaf, C. P., Schirmacher, P., Endris, V., Stenzinger, A., Budczies, J.

“…Homologous repair deficiency (HRD) is present in many cancer types at variable prevalence and can indicate response to platinum-based chemotherapy and PARP…”
Get full text

The immune microenvironment in EGFR- and ERBB2-mutated lung adenocarcinoma by Kirchner, M., Kluck, K., Brandt, R., Volckmar, A.-L., Penzel, R., Kazdal, D., Endris, V., Neumann, O., Seker-Cin, H., Goldschmid, H., Glade, J., Allgäuer, M., Kriegsmann, M., Winter, H., Muley, T., Perner, S., Frost, N., Reck, M., Fröhling, S., Schirmacher, P., Thomas, M., Budczies, J., Christopoulos, P., Stenzinger, A.

“…Targeted therapies have improved survival and quality of life for patients with non-small-cell lung cancer with actionable driver mutations. However, epidermal…”
Get full text

RNA-based determination of ESR1 and HER2 expression and response to neoadjuvant chemotherapy by Denkert, C., Loibl, S., Kronenwett, R., Budczies, J., von Törne, C., Nekljudova, V., Darb-Esfahani, S., Solbach, C., Sinn, B.V., Petry, C., Müller, B.M., Hilfrich, J., Altmann, G., Staebler, A., Roth, C., Ataseven, B., Kirchner, T., Dietel, M., Untch, M., von Minckwitz, G.

“…Hormone and human epidermal growth factor receptor 2 (HER2) receptors are the most important breast cancer biomarkers, and additional objective and…”
Get full text

Thymosin beta 15A (TMSB15A) is a predictor of chemotherapy response in triple-negative breast cancer by Darb-Esfahani, S, Kronenwett, R, von Minckwitz, G, Denkert, C, Gehrmann, M, Rody, A, Budczies, J, Brase, J C, Mehta, M K, Bojar, H, Ataseven, B, Karn, T, Weiss, E, Zahm, D M, Khandan, F, Dietel, M, Loibl, S

“…Background: Biomarkers predictive of pathological complete response (pCR) to neoadjuvant chemotherapy (NACT) of breast cancer are urgently needed. Methods:…”
Get full text

Microfluidic sampling system for tissue analytics by Hokkanen, A, Stuns, I, Schmid, P, Kokkonen, A, Gao, F, Steinecker, A, Budczies, J, Heimala, P, Hakalahti, L

“…We have developed a microfluidics based sampling system for tissue analytics. The proof-of-concept of the sampling system was demonstrated by extracting lipid…”
Get full text

Locally recurrent colorectal cancer: results of surgical therapy by Kruschewski, M., Ciurea, M., Lipka, S., Daum, S., Moser, L., Meyer, B., Gröne, J., Budczies, J., Buhr, H. J.

“…Purpose Up to 20 % of colorectal cancer patients develop recurrent disease despite standardized surgical techniques and multimodal treatment strategies…”
Get full text

Securin (hPTTGI) expression is regulated by β-catenin/TCF in human colorectal carcinoma by HLUBEK, F, PFEIFFER, S, BUDCZIES, J, SPADERNA, S, JUNG, A, KIRCHNER, T, BRABLETZ, T

“…Overexpression of the transcriptional activator beta-catenin, mostly owing to loss-of-function mutations of the adenomatous polyposis coli (APC) tumour…”
Get full text

Metabolome analysis of solid tumors by Budczies, J

“…Metabolomics, the newest of the omics sciences that also include genomics, transcriptomics and proteomics, has matured into a reliable high-throughput…”
Get full text

On the quality of the external post-mortem examination in cases of fatal head trauma : A comparison of death certificate and forensic autopsy by Kronsbein, K, Budczies, J, Pfeiffer, H, Karger, B, Wittschieber, D

“…In Germany it is required by law that basically every type of physician needs to be capable of executing a correct external post-mortem examination of a…”
Get full text

Standardized determination of tumor-infiltrating lymphocytes in breast cancer : A prognostic marker for histological diagnosis by Denkert, C, Loibl, S, Budczies, J, Wienert, S, Klauschen, F

“…Tumor-infiltrating lymphocytes (TILs) have been identified as prognostic parameter in breast cancer. The aim of this review article is to provide an overview…”
Get full text

443 PARP is expressed in all subtypes of early breast cancer and is a predictive factor for response to neoadjuvant chemotherapy by von Minckwitz, G, Müller, B, Loibl, S, Blohmer, J.U, duBois, A, Huober, J, Kandolf, R, Budczies, J, Denkert, C

Get full text

(1+1)-dimensional baryons from the SU( N) color-flavor transformation by Budczies, J., Nonnenmacher, S., Shnir, Ya, Zirnbauer, M.R.

“…The color-flavor transformation, an identity that connects two integrals, each of which is over one of a dual pair of Lie groups acting in the fermionic Fock…”
Get full text